The debate over the merits of prostate cancer screening by using the prostate specific antigen (PSA) blood test is not likely to go away any time soon. However, the majority of men between ages 50-70 will continue to have blood tests to screen for prostate cancer (PCa). According to experts, more than two-thirds of men with an elevated PSA will not be diagnosed with PCa... keep reading

The entertainment value of a good suspense movie lies in keeping the audience guessing. Is the bad guy actually dead? Has the evil ghost actually left the haunted house for good? Why is the possessed person’s head still spinning if the demon was actually cast out? Moviegoers who are into such films happily pay for keep reading

The University of California/Los Angeles (UCLA) completed a study that not only affirms our work at the Sperling Prostate Center but also offers terrific news for all prostate cancer patients. A team from their medical school’s Department of Radiology completed a retrospective study of in-bore MRI-guided prostate biopsy cases. They found that... keep reading

Let’s face it, guys. We’re not getting any younger. In fact, society is getting older. The Population Reference Bureau tells us that in the U.S, the number of those age 65 and up is expected to nearly double from 52 million in 2018 to 95 million by 2060... keep reading

Back in the days of elementary school, birthday party invitations held a lot of status meaning. They were early lessons in exclusion and inclusion. If you got one, the message was clear: you were “in” with that kid. Also, the wording of the invitation was another clear message. It told you everything you needed to keep reading

WARNING: The following information might make you wonder if your prostate gland has been exposed to harmful chemicals. Let’s start with some old news about Agent Orange. The years are 1962-70. U.S. troops are fighting in Vietnam. A plant killer called Agent Orange (named for the orange stripe on its 55- gallon storage drums) is keep reading

There’s a new kid on the block when it comes to androgen-deprivation therapy (ADT) for metastatic prostate cancer (mPCa). ADT has been the conventional standard of care once the cancer has begun to spread to distant parts of body such as bones or other organs. ADT uses... keep reading

Do you watch YouTube videos? If so, and you’re between ages 45-64, you’re among the 500 million viewers your age who make up YouTube’s worldwide ad audience. If you’re male, you’re also among the 1 out of every 52 U.S. men between ages 50-59 who will learn they have prostate cancer (PCa), and closer to keep reading

“For the last 40 years the prostate’s been unusual in that we’ve been interrogating men who were at risk of prostate cancer with a random needle deployment of the organ, which we don’t do in any other organ systems in relation to cancer. I think we always knew it was unreliable, and that the diagnosis was uncertain, but I think we just didn’t realize... keep reading

If it shrinks BPH, can it kill prostate cancer? That’s the question that sparked “the first long-term prospective randomized-controlled study of an intraprostatic molecular injectable treatment for low grade localized PCa to be reported.” The authors of the study include luminaries from sites such as Johns Hopkins and Mt. Sinai/Icahn School of Medicine... keep reading